A @entity5 -penetrating peptide enhances circulation-independent targeting of peritoneal XXXX .

@entity1 @entity43 @entity632 @entity137 @entity5 @entity19 @entity1661 @entity189 @entity941 @entity7730 @entity3 @entity19285 @entity298
UNASSIGNED: @entity298 is a major source of morbidity and mortality in @entity1 with advanced @entity1661 . @entity7730 ( @entity7730 ) is an area of intense interest given its efficacy in @entity43 . However, @entity7730 suffers from poor drug penetration into peritoneal @entity5 . As such, extensive cytoreductive surgery is required prior to @entity7730 . Here, we explore the utility of @entity19285 , a @entity5 -penetrating peptide, for improved @entity5 -specific penetration of intraperitoneal compounds and enhanced @entity7730 in @entity19 . Intraperitoneally administered @entity19285 significantly enhanced penetration of an attached @entity941 into disseminated peritoneal @entity5 nodules. The penetration was @entity5 -specific, circulation-independent, and mediated by the neuropilin-binding RXXK tissue-penetration peptide motif of @entity19285 . Q- @entity19285 , which fluoresces upon cleavage, including the one that leads to RXXK activation, specifically labeled peritoneal metastases displaying different growth patterns in @entity19 . Importantly, @entity19285 enhanced intratumoral entry of intraperitoneally co-injected dextran to approximately 300% and @entity632 to 250%. Intraperitoneal @entity19285 / @entity632 combination therapy inhibited the growth of bulky peritoneal @entity5 and reduced systemic @entity137 . @entity19285 delivered attached @entity941 and co-applied nanoparticles deep into fresh @entity1 peritoneal @entity3 explants. These results indicate that intraperitoneal @entity19285 co-administration serves as a simple and effective strategy to facilitate @entity5 detection and improve the therapeutic index of @entity7730 for peritoneal @entity189 .
